A Randomized, Double-Blind, Placebo Controlled , Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI Following Cardiac Surgery
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Teprasiran (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Sponsors Quark Pharmaceuticals
- 27 Jul 2017 According to a Quark Pharmaceuticals media release, data from this study will be submitted for presentation at an upcoming medical congress.
- 27 Jul 2017 Results published in a Quark Pharmaceuticals Media Release.
- 27 Jul 2017 Status changed from active, no longer recruiting to completed, according to a Quark Pharmaceuticals media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History